MYL9 and inflammatory bowel disease: Importantly, the plasma Myl9 levels in IBD patients, especially UC, were positively correlated with their disease severity, suggesting that plasma Myl9 is a viable new biomarker indicating the severity of disease activity of IBD, especially in patients with UC.